» Articles » PMID: 33836067

Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Following the Largest Initial Epidemic Wave in the United States: Findings From New York City, 13 May to 21 July 2020

Overview
Journal J Infect Dis
Date 2021 Apr 9
PMID 33836067
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: New York City (NYC) was the US epicenter of the spring 2020 coronavirus disease 2019 (COVID-19) pandemic. We present the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and correlates of seropositivity immediately after the first wave.

Methods: From a serosurvey of adult NYC residents (13 May to 21 July 2020), we calculated the prevalence of SARS-CoV-2 antibodies stratified by participant demographics, symptom history, health status, and employment industry. We used multivariable regression models to assess associations between participant characteristics and seropositivity.

Results: The seroprevalence among 45 367 participants was 23.6% (95% confidence interval, 23.2%-24.0%). High seroprevalence (>30%) was observed among black and Hispanic individuals, people from high poverty neighborhoods, and people in healthcare or essential worker industry sectors. COVID-19 symptom history was associated with seropositivity (adjusted relative risk, 2.76; 95% confidence interval, 2.65-2.88). Other risk factors included sex, age, race/ethnicity, residential area, employment sector, working outside the home, contact with a COVID-19 case, obesity, and increasing numbers of household members.

Conclusions: Based on a large serosurvey in a single US jurisdiction, we estimate that just under one-quarter of NYC adults were infected in the first few months of the COVID-19 epidemic. Given disparities in infection risk, effective interventions for at-risk groups are needed during ongoing transmission.

Citing Articles

Infection Rate and Risk Factors of SARS-CoV-2 Infection in Retail Workers at the Onset of the COVID-19 Pandemic, Quebec, Canada.

Santerre K, Theriault M, Brousseau N, Langlois M, Arnold C, Pelletier J Infect Dis Rep. 2024; 16(6):1240-1253.

PMID: 39728020 PMC: 11675805. DOI: 10.3390/idr16060098.


Longitudinal determination of seroprevalence and immune response to SARS-CoV-2 in a population of food and retail workers through decentralized testing and transformation of ELISA datasets.

Djaileb A, Parker M, Lavallee E, Stuible M, Durocher Y, Theriault M PLoS One. 2024; 19(12):e0314499.

PMID: 39680559 PMC: 11649073. DOI: 10.1371/journal.pone.0314499.


Development of hybrid immunity during a period of high incidence of Omicron infections.

Frei A, Kaufmann M, Amati R, Butty Dettwiler A, von Wyl V, Annoni A Int J Epidemiol. 2023; 52(6):1696-1707.

PMID: 37407273 PMC: 10749742. DOI: 10.1093/ije/dyad098.


Disproportionate impacts of COVID-19 in a large US city.

Fox S, Javan E, Pasco R, Gibson G, Betke B, Herrera-Diestra J PLoS Comput Biol. 2023; 19(6):e1011149.

PMID: 37262052 PMC: 10234557. DOI: 10.1371/journal.pcbi.1011149.


Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants.

Jenkins M, Tran D, Flores E, Kupferwasser D, Pickering H, Zheng Y Front Immunol. 2023; 14:1139915.

PMID: 37153624 PMC: 10154521. DOI: 10.3389/fimmu.2023.1139915.